Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 10 | PfizerINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02192697 | An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations | terminated | Phase 1 / Phase 2 | 124 | Astellas Pharma IncINDUSTRY | 3 | Nov 14, 2024 | clinicaltrials |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | terminated | Phase 1 / Phase 2 | 12 | Atara BiotherapeuticsINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT01318642 | Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas | terminated | Phase 2 | 10 | NantBioScience, Inc.INDUSTRY | 13 | Nov 8, 2024 | clinicaltrials |
| NCT04220775 | Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04989218 | Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)(ICC) | terminated | Phase 1 / Phase 2 | 1 | University of Alabama at BirminghamOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04493619 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | terminated | Phase 1 / Phase 2 | 37 | Opna Bio LLCINDUSTRY | 2 | Nov 4, 2024 | clinicaltrials |
| NCT03153982 | Ruxolitinib in Operable Head and Neck Cancer | terminated | Phase 2 | 16 | University of California, San FranciscoOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT03393936 | Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 66 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT01088906 | Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC(Phalcis) | terminated | Phase 2 | 57 | Spanish Lung Cancer GroupOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 68 | OBI Pharma, IncINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05492045 | A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 22 | InventisBio Co., LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03879798 | DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT04139317 | Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | terminated | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 16 | Oct 9, 2024 | clinicaltrials |
| NCT04323436 | Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | terminated | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | Oct 9, 2024 | clinicaltrials |
| NCT04003896 | A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma | terminated | Phase 2 | 4 | Milton S. Hershey Medical CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04536077 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | terminated | Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | terminated | Phase 1 / Phase 2 | 13 | BioNTech SEINDUSTRY | 2 | Oct 2, 2024 | clinicaltrials |
| NCT05397171 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | terminated | Phase 1 / Phase 2 | 17 | AstraZenecaINDUSTRY | 2 | Oct 1, 2024 | clinicaltrials |
| NCT03177187 | Combination Study of AZD5069 and Enzalutamide.(ACE) | terminated | Phase 1 / Phase 2 | 30 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 26, 2024 | clinicaltrials |
| NCT05191797 | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 3 | University of WashingtonOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT00667628 | Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 54 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00687596 | Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy | terminated | Phase 2 | 52 | Taiho Oncology, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01904253 | A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy | terminated | Phase 2 | 18 | Taiho Oncology, Inc.INDUSTRY | 3 | Sep 5, 2024 | clinicaltrials |
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | terminated | Phase 2 | 12 | Roberto PiliOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix(NIVIX) | terminated | Phase 1 / Phase 2 | 4 | Michelle S LudwigOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT01284348 | To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 26 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 29, 2024 | clinicaltrials |
| NCT04123704 | Sitravatinib in Metastatic Breast Cancer | terminated | Phase 2 | 3 | Xiang ZhangOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT00791154 | QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer(SCLC) | terminated | Phase 1 / Phase 2 | 213 | NantCell, Inc.INDUSTRY | 0 | Aug 23, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT06206278 | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma | terminated | Phase 2 | 6 | LianBio LLCINDUSTRY | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03050554 | SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 2 | Andrew SharabiOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | terminated | Phase 1 / Phase 2 | 9 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03853317 | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy | terminated | Phase 2 | 9 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | terminated | Phase 1 / Phase 2 | 79 | Elucida OncologyINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04497038 | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy | terminated | Phase 1 / Phase 2 | 3 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | terminated | Phase 1 / Phase 2 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 5, 2024 | clinicaltrials |
| NCT00998166 | A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy | terminated | Phase 2 | 12 | Columbia UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT04212221 | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients | terminated | Phase 1 / Phase 2 | 89 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | terminated | Phase 1 / Phase 2 | 37 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT06507891 | A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets | terminated | Phase 1 / Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 10 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02314052 | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 21 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 3 | Jul 11, 2024 | clinicaltrials |
| NCT05009953 | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer | terminated | Phase 2 | 17 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 11, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 19, 2024source: clinicaltrials